I believe there are very few interventions studies to improve mental health and well-being, using mobile apps and having a protocol can encourage others to replicate similar studies and evaluate the effectiveness of mobile app use.
I suggest authors to add more detail to the design of the study which I stated below.
Introduction: It is well-written. I suggest to include the description of the HeadGear app which appears in the methods section. It will help readers to understand how the app is developed, underpinning theories.
Sample: 2100 sample size was suggested, but could be more precise whether it is a total or each group? Also currently authors stated men and women are recruited, but not mentioning exact numbers. Description of the power calculation appears much later (pg 13, ln 25), and I think this section could be moved up to the sample section or at least could be flagged up. Also, it is helpful for readers to know how authors balance up participants in relation to marital status, age, occupational position, income, education, ethnic groups and employment status (part-time vs full time) and durations that are related to mental health.
Sampling weights: Authors could add more description about base information to determine the weights and how to derive appropriate weights.
Safety: Authors took great care for those who are mentally ill at the baseline. But what about those who might have developed emotional disturbance during the trial? Would they be excluded or referred? Is there any contact point for the participants to discuss their concern? Dissemination -I suggest removing this section because it is not relevant.
Discussion:
Authors stated that the results may not be applicable to the rest of the population; however, they could also state whether the app is useful to other populations.
Good work!

REVIEWER
Jan R. Boehnke University of Dundee, UK REVIEW RETURNED 05-Jan-2018
GENERAL COMMENTS
The manuscript "A smartphone application for preventing depression: Study protocol for a workplace randomised controlled trial" presents a protocol for a study evaluating the impact of a smartphone app on decreasing depressive symptomatology at three months (single primary endpoint; outcome: PHQ-9) in employed adults in male-dominated industries who are likely to be not depressive (PHQ-9 score < 14 at baseline). The intervention intends to use behavioural activation and mindfulness techniques to achieve this goal.
The protocol reads overall well and gives a good impression of the study design and steps involved. I think it is nevertheless overall lacking in detail which I will detail especially for the (statistical) methods since I was asked to perform a review of the (statistical) methods and study design aspect. My comments are mainly organised in their order of appearance in the manuscript.
1) The only point that is not clear-cut related to methodological and analytical aspects of the study is related to lack of clinical detail. The intervention is not described with view to its specific elements nor are the mechanisms explained that the app employs to increase the use of BA/ mindfulness activities and consequently how these lead to a change in depressive symptoms (the primary outcome). This is of central importance for clinical applications and plausibility since it generates further hypotheses (the presentation of a logic model would help), but from a methodological point of view it would also help to understand the control condition (see next comments) by illustrating which of the mechanisms are not in place.
[Please note that mechanisms means here both procedural aspects of the app, i.e. what kind of activities are suggested etc., as well as in the classic sense of what the causal pathways are of how the building blocks of the intervention affect change, e.g., Kazdin, 2009, Psychotherapy Research, 19, 418-428] .
2) Page 7: For the interpretation of treatment effects a clearly defined control condition is needed. From the current description provided by the authors, it is unclear to me what the control condition will be like. What will people actually do? How and in which mechanisms of change does the control condition differ from the intervention and which aspects are the same? How will it be ensured that the time spent on the control application will be similar to the intervention? And similarly, how is ensured that the control condition is as engaging as the intervention, but not leading to BA and mindfulness
3) The section on randomisation (page 9) could be more specific. At least the management system used could be specified and how it is tied in to the smartphone app.
4) The two references used to justify assumptions about the PHQ-9's validity [35, 57] are studies that were conducted in primary care settings. Results from primary care do not (necessarily) translate into general population settings and an effort should be made to report more context-appropriate diagnostic validity results here.
5) The same extends also to the reliability estimates reported for the GAD-2 in the following section, which again is taken form primary care, not from work-place or general population settings. Appropriate estimates should be reported here as well.
6) Since all measures of reliability and validity are sample and population dependent, this should be checked for all measures used in this study. Since the authors are targeting purposively non-clinical and mainly screen-negative populations it is unlikely that any reliability and validity statistics from clinical settings are appropriate to describe the performance of instruments in workplace / general population settings. 9a) Page 12: The primary outcome needs to be specified much more clearly. At the moment it could be scoring or algorithm and "across" is unclear. Suggestion: "The primary outcome measure of the study will be the level of depressive symptomatology as measured by the PHQ-9 sum score at 3-month follow up." 9b) Ideally, here or in the statistical analysis section it would also be defined how many days +/-the actual 3months/90days the outcome measurement is allowed to vary to be still acceptable.
10) The statistical analysis section should clearly state the exact model that will be used to decide whether the intervention was effective or not. Since this protocol will be the only document that will be available for the wider public to scrutinise the result of the study, it is absolutely key that the authors determine the exact model that will be used and the exact decision rules when to transform and when to include further variables. Without that, the protocol does not fulfil its purpose and the consequences to which this leads were visible in the recent debate around the PACE trial. I am not particularly concerned about detail regarding secondary outcomes and secondary analyses, since they, whether pre-planned or not, cannot be used to make a decision or any claims about the effectiveness of the intervention.
11) The protocol does not specify how missing data and drop-outs will be handled.
12) Since no analysis model is specified in the analysis section (see above) and the sample size calculation also does not specify which statistical model was assumed, it is unclear whether the sample size calculation matches the assumptions of the analytic model that will be used to analyse the data.
13) Page 13, sample size section: After discussing effect sizes of similar interventions and aggregates from meta-analyses, the authors state that they aimed with their sample size to "detect a difference of 2 points on the PHQ-9 scale". It is unclear how effect sizes from previous meta-analyses are connected to the 2 point difference. This should be clarified.
14) The passage on lack of power for dichotomous outcomes is somewhat surprising. The primary outcome is the PHQ-9 score and the study is powered to show a certain difference on that measure. This is the only difference that can be interpreted after the study as (a) a confirmatory hypothesis test and (b) as being a priori powered. All other analyses have not been part of the sample size calculation (e.g., controlling for multiplicity of endpoints and calculating an appropriate sample size for a dichotomous outcome) and by definition are not "powered" at all. They are exploratory and with view to an evaluation of the intervention irrelevant since they are not part of the primary outcome analysis. This part could be dropped.
15) Throughout the manuscript the authors refer repeatedly to the PHQ-2 as an assessment tool for anxiety. While there is such an instrument, it is a screener for depression based on the first two DSM-IV criteria for depression. The authors probably refer to the GAD-2 as stated on page 10, lines 11/12.
VERSION 1 -AUTHOR RESPONSE
A smartphone application for preventing depression: Study protocol for a workplace randomised controlled trial
Response to Reviewers Comments
Reviewer Reviewers Comments How Addressed
Reviewer 1
I would like to know more about: a) the specific firms from which participants are to be recruited;
We thank Reviewer 1 for highlighting this omission. We have now included additional information about the industry partners, specifically their industry group and locations. We have stopped short of naming each organisation in line with our ethics approval.
b) methods to prevent contamination (diffusion) of the intervention effect from experimental vs control participants working for the same firm;
We agree that this is a potential issue, as it is in most controlled trials. We have now added an acknowledgement of this in the limitations section. However, we have also noted that given the size of the organisations, the stigma associated with mental health and the fact that the smartphone based application is designed for individual to undertake exercises in private, we think that any contamination is unlikely. c) justification for including participants with PHQ-9 scores 10-14 (since many of these patients will have moderate depression that would benefit from treatment);
As noted by Reviewer 1, the 10-14 scoring range of the PHQ-9 has been identified as a diagnostic 'grey zone' by the original authors (Kroenke & Spitzer, 2002) . Investigations of optimal cut-off scores have tended to find improved validity and senstitivity when the higher cut off scores are used (Manea, Gilbody, & McMillan, 2012) . One of the aims of our study is to be able to compare the efficacy of the intervention as a universal, selective and indicated prevention approach. To test indicated prevention we wanted to include people with sub-syndromal depression. The difficulty that may arise from this, as identified by Reviewer 1, is distinguishing between mild depression from sub-syndromal depression and therefore between prevention and treatment. We have included an expanded discussion about this in the limitation section of the paper.
d) procedures to be employed to keep participants engaged in the study (reminders and a lottery may not be sufficient).
We agree that maximising engagement and follow up is essential. We have provided greater detail around the procedures aimed at increasing followup, which have been informed by previous research (e.g. Andrews, Nonnecke & Preece, 2003) . We have also made specific allowances (see power calculation) for the types of followup rates typically seen in this type of sample (estimated at around 60%).
On page 10, line 4, please give the sensitivity and specificity at a specific cutoff score.
We apologise for this omission and have included more information to clarify the sensitivity and specificity.
Reviewer 2
I suggest to include the description of the HeadGear app which appears in the methods section. It will help readers to understand how the app is developed, underpinning theories.
We thank Reviewer 2 for this suggestion.
On page 6 and 7, in the methods section, we have provided much more detail about the intervention and the underlying theoretical concepts. 2100 sample size was suggested, but could be more precise whether it is a total or each group
We apologise for this confusion and have clarified that the total sample will comprise of at least 2100 employed participants.
Also currently authors stated men and women are recruited, but not mentioning exact numbers.
On page 6 we have added that both males and females will be recruited, though it is anticipated that more than half of the sample will be men due to the focus on male dominated industries.
Description of the power calculation appears much later (pg 13, ln 25), and I think this section could be moved up to the sample section or at least could be flagged up.
We thank Reviewer 2 for this suggestion and have now highlighted to readers that the sample calculation will be provided in a subsequent section.
How authors balance up participants in relation to marital status, age, occupational position, income, education, ethnic groups and employment status (part-time vs full time) and durations that are related to mental health.
As noted in page 9 of the methods section, the randomisation process will stratify by industry group, to ensure this key variable is balanced between the groups. Random imbalance in other important variables, such as age, gender and job details will be examined using chi square tests. An outline of this is now included in the Analysis Plan on page 12.
As noted below, Reviewer 3 has suggested that this section be removed as it does not relate to the primary outcome.
Safety: Authors took great care for those who are mentally ill at the baseline. But what about those who might have developed emotional disturbance during the trial? Would they be excluded or referred? Is there any contact point for the participants to discuss their concern?
We apologise for this confusion. The detailed "Safety Protocol" outlined on page 11 section will be used for those who develop significant symptoms during the trial. This has now been made clearer.
Dissemination -I suggest removing this section because it is not relevant.
This section was included as BMJ Open requires a dissemination section as part of its formatting guidelines. If the editorial staff agree and would like this section removed, we are happy for this to occur.
The intention of this sentence was not to say that the intervention may not be applicable to other populations but to highlight the limitations of volunteerbased research trials. We have reworded this paragraph in line with the Reviewer's suggestion.
Reviewer 3
Lack of clinical detail -The intervention is not described with view to its specific elements nor are the mechanisms explained that the app employs to increase the use of BA/ mindfulness activities and consequently how these lead to a change in depressive symptoms (the primary outcome) -please note that mechanisms means here both procedural aspects of the app, i.e. what kind of activities are suggested etc., as well as in the classic sense of what the causal pathways are of how the building blocks of the intervention affect change
We thank Reviewer 3 for this most useful suggestion. We have now greatly expanded our description of the clinical aspects of the smartphone application and their theoretical basis (on pages 6 and 7)
Page 7: For the interpretation of treatment effects a clearly defined control condition is needed -it is unclear to me what the control condition will be like.
What will people actually do?
How and in which mechanisms of change does the control condition differ from the intervention and which aspects are the same? -How will it be ensured that the time spent on the control application will be similar to the intervention? -How is it ensured that the control condition is as engaging as the intervention, but not leading to BA and mindfulness
We agree with Reviewer 3 that this is a key point that we were not clear enough about. The control condition is intended to control for the potential beneficial effects of mood monitoring and being prompted to think about your mood regularly, which occurs when a mental health application is used, but is separate to our proposed therapeutic content. In order to make this clearer we have re-written the control description on page 8, to know read:
Control condition: mood monitoring smartphone application
The control condition is a smartphone application that, to the user, will have the same name and a virtually identical look and 'feel' as Headgear. However, there is no skill development and no components of behavioural activation or mindfulness therapy. To control for the other components of the HeadGear application, the control condition will encourage users to use the inbuilt mood monitor daily over a 30-day period. To ensure consistent approaches to reminders and prompting between the two applications, participants in the control group will receive daily reminders to record their moods via the control smartphone application. In conjunction to this, participants are able to review their 'mood history' in a calendar which displays the mood recorded across each day. Participants will also have access to the risk calculator which will provide participants with individualised risk feedback. Controlling for mood monitoring, which is a common feature of many commercially available smartphone applications, is essential as this alone may bring awareness to an individual's mood and the allow them to gain greater understanding of the causative behaviours related to their mood thereby bringing about behaviour change and associated improvements in mood.
The section on randomisation (page 9) could be more specific. At least the management system used could be specified and how it is tied in to the smartphone app.
More information has been provided detailing at what stage the randomisation process happens and its linkage with the smartphone application.
Two references used to justify assumptions about the PHQ-9's validity [35, 57] are studies that were conducted in primary care settings which create translation issues -report more context appropriate diagnostic validity results…..reliability estimates reported for the GAD-2 -taken form primary care, not from work-place or general population settings
We agree with Reviewer 3 regarding this issue and thank them for highlighting this. Additional references have been provided to justify the validity and reliability of the measure in general population settings.
Since all measures of reliability and validity are sample and population dependent, this should be checked for all measures used in this study -it is unlikely that any reliability and We have now made it clear in both the analysis section and when describing the sample size calculations that two sided models will be used.
Page 12: The primary outcome needs to be specified much more clearly. At the moment it could be scoring or algorithm and "across" is unclear. Suggestion: "The primary outcome measure of the study will be the level of depressive symptomatology as measured by the PHQ-9 sum score at 3-month follow up."
We apologise for this lack of clarity. The primary outcome will be the level of depression symptomatology, as measured by the total PHQ-9 score. The primary end point will be 3 month follow up. This has now been made much clearer on
Ideally, here or in the statistical analysis section it would also be defined how many days +/-the actual 3months/90days the outcome measurement is allowed to vary to be still acceptable.
We thank the reviewer for this good suggestion. Having undertaken a range of similar trials previously, we are aware that it can be difficult to get individuals using a smartphone application to complete follow up questions at the exact time we would like. As noted in our paper, we have ethics approval to undertake phone reminders, which should assist with follow up rates, but our expectation is that we will need to allow a wide window of response times (up to 90 days). We have now clarified this and also discussed the limitations associated with this.
The statistical analysis section should clearly state the exact model that will be used to decide whether the intervention was effective or not. Since this protocol will be the only document that will be available for the wider public to scrutinise the result of the study, it is absolutely key that the authors determine the exact model that will be used and the exact decision rules when to transform and when to include further variables. Without that, the protocol does not fulfil its purpose and the consequences to which this leads were visible in the recent debate around the PACE trial. The protocol does not specify how missing data and drop-outs will be handled.
We have expanded and reworded the analysis plan section to be as clear about the planned analysis as possible.
Clearly it is not possible to make assumptions about the distribution of variables until the data is collected, but we have tried to make the way in which these will be dealt with as clear as possible. We have also included additional information about how missing data will be handled.
Since no analysis model is specified in the analysis section (see above) and the sample size calculation also does not specify which statistical model was assumed, it is unclear whether the sample size calculation matches the assumptions of the analytic model that will be used to analyse the data.
We apologise for this lack of clarity. The power calculations did indeed use the same types of mixed models outlined in the now expanded and clearer statistical analysis section. This has been made clearer on page 13.
Page 13, sample size section: After discussing effect sizes of similar interventions and aggregates from meta-analyses, the authors state that they aimed with their sample size to "detect a difference of 2 points on the PHQ-9 scale". It is unclear how effect sizes from previous meta-analyses are connected to the 2 point difference. This should be clarified
We also apologise for this, which is in fact a typographical error. The power calculations were based on the need to be able to detect an effect size of 0.2 with regards to the total PHQ scales, which is the mid-point of the two estimates discussed. We have obviously corrected this and apologise for the confusion caused.
The passage on lack of power for dichotomous outcomes is somewhat surprising. The primary outcome is the PHQ-9 score and the study is powered to show a certain difference on that measure. This is the only difference that can be interpreted after the study as (a) a confirmatory hypothesis test and (b) as being a priori powered. All other analyses have not been part of the sample size calculation (e.g., controlling for This passage and the more detailed discussion of the analysis of dichotomous outcomes has been deleted in line with this suggestion. multiplicity of endpoints and calculating an appropriate sample size for a dichotomous outcome) and by definition are not "powered" at all. They are exploratory and with view to an evaluation of the intervention irrelevant since they are not part of the primary outcome analysis. This part could be dropped
Throughout the manuscript the authors refer repeatedly to the PHQ-2 as an assessment tool for anxiety. While there is such an instrument, it is a screener for depression based on the first two DSM-IV criteria for depression. The authors probably refer to the GAD-2 as stated on page 10, lines 11/12.
We thank Reviewer 3 for highlighting this error. Any mention of the PHQ-2 has now been changed to the GAD-2 throughout the paper. 
GENERAL COMMENTS
The revision of the manuscript "A smartphone application for preventing depression: Study protocol for a workplace randomised controlled trial" shows a great improvement in detail and focus on the aspects of trial management and all aspects relating to the analysis. I nevertheless have a few further comments.
1) On page 9 the authors added "Additionally, participants will be stratified by industry." Please specify this stratification exactly here and potentially in the analysis section if used as a design variable (which categories are being used and if used in analysis, how will they be incorporated)?
2) On page 10 the authors now specified that measures will be accepted within a 90-day range. This should be clarified: Is this "up to 90 days after the scheduled assessment" or "from 45 days before until 45 days after the scheduled assessment" (or anything else)?
3) Detail on the statistical analysis has been greatly improved and is appropriate for a study protocol. And since this is a protocol, I therefore stop requesting further changes. But I want to make the authors aware that the description still leaves many degrees of freedom and the exact analytic model is not defined. Any report built solely on the information presented here would be wide open for criticism that either builds on assuming the authors made final decisions on the specifics after analysing the data or that the authors interpreted something differently than reviewers and consumers of their research. At this stage I am just assuming that the authors will publish an a priori statistical analysis plan that provides the exact information that is missing here. This also relates to responses by the authors that certain aspects cannot be known before the data have been assessed (e.g., their distribution). While this is correct, the analysis nevertheless needs to specify a priori which analysis would be treated as the main analysis which decides about the efficacy (transformed or untransformed to stick with the example) and which analysis only provides additional scrutiny in the form of a sensitivity analysis. But again, the statistical analysis plan would be the place to sort this level of detail.
4) It is still not clear whether control variables (and which) will be used in the model or whether only the treatment allocation will be used as a predictor.
5) The authors state that they will test baseline variables for random imbalance and include them in the models. While certainly possible for exploratory follow-up analyses, this practice has been clearly identified as not recommended. For a brief overview see for example the EMA Guideline on adjustment for baseline covariates in clinical trials (EMA/CHMP/295050/2013 , 26.02.2015 or Roberts (1999, BMJ, 319:185) or in more detail Senn (1994 , Statistics in Medicine, 13, 1715 -1726 . Again, this level of detail may pertain to the statistical analysis plan (which would specify the exact model to be tested for the primary hypothesis), but it seemed a necessary comment at this point.
VERSION 2 -AUTHOR RESPONSE Reviewer 3 states "shows a great improvement in detail and focus on the aspects of trial management and all aspects relating to the analysis", and has only minor comments. 1) On page 9 the authors added "Additionally, participants will be stratified by industry." Please specify this stratification exactly here and potentially in the analysis section if used as a design variable (which categories are being used and if used in analysis, how will they be incorporated)?
We thank the reviewer for raising this important oversight which was based on previous plan for analysis which has since been modified and this section has accordingly been removed.
Clarification of this point has been made within the manuscript, it refers to "up to 90 days after the scheduled assessment".
3) Detail on the statistical analysis has been greatly improved and is appropriate for a study protocol. And since this is a protocol, I therefore stop requesting further changes. But I want to make the authors aware that the description still leaves many degrees of freedom and the exact analytic model is not defined. Any report built solely on the information presented here would be wide open for criticism that either builds on assuming the authors made final decisions on the specifics after analysing the data or that the authors interpreted something differently than reviewers and consumers of their research. At this stage I am just assuming that the authors will publish an a priori statistical analysis plan that provides the exact information that is missing here.
This also relates to responses by the authors that certain aspects cannot be known before the data have been assessed (e.g., their distribution). While this is correct, the analysis nevertheless needs to specify a priori which analysis would be treated as the main analysis which decides about the efficacy (transformed or untransformed to stick with the example) and which analysis only provides additional scrutiny in the form of a sensitivity analysis. But again, the statistical analysis plan would be the place to sort this level of detail.
We appreciate the reviewer's meticulous review of this section and subsequent improving of this manuscript, the reviewer seeks no further changes but only an a priori statistical analysis plan 4) It is still not clear whether control variables (and which) will be used in the model or whether only the treatment allocation will be used as a predictor.
We now explicitly state that the model will include intervention allocation and occasion of measurement as 'predictors' in the planned MMRM ANOVA.
There appears a slight misinterpretation on this point that requires clarification, the manuscript did not state that we would 'test' for imbalance -as a significant inferential test can only reflect Type I error.
Rather, we state that variables substantially imbalanced at baseline will be tentatively included in models. We feel that this is not dissonant with Senn's views in the current of the intervention environment in which we operate: not all trials are drug trials. He has argued that 'important' covariates should be included in models. In contrast to pharma trials conducted to meet guidelines for approval, it is difficult to establish in advance which factors are likely to be important. We do not have the same scope of using the current trial and covariate behaviour to inform future intervention development. Nevertheless, characterising these analyses as tentative was intended to indicate that they were designed to explore the robustness of the outcomes to imbalance. Modifications to the text have been made to clarify this.
VERSION 3 -REVIEW
REVIEWER
Jan R. Boehnke University of Dundee, UK REVIEW RETURNED 30-May-2018
GENERAL COMMENTS
I think two comments are left, but one could be related to the submission potentially providing the wrong version of the manuscript.
The authors wrote that they addressed the following point (full quote incl. response): "1) On page 9 the authors added "Additionally, participants will be stratified by industry." Please specify this stratification exactly here and potentially in the analysis section if used as a design variable (which categories are being used and if used in analysis, how will they be incorporated)? RESPONSE: We thank the reviewer for raising this important oversight which was based on previous plan for analysis which has since been modified and this section has accordingly been removed."
Nevertheless, in the version in the online system the sentence about stratification is still included.
Additionally, I am still not clear on what statistical model the authors will use and how it is connected to their hypotheses. It is stated that a repeated-measurement mixed model will be used to analyse the data for the primary outcome (and that the sample size calculation was performed for this model). Nevertheless, the hypothesis the authors set out to test is the difference in PHQ-9 sum scores at 3 months -which necessitates a planned comparison at only that assessment, which can be derived from the results of the mixed model (either via a post-hoc test or a contrast This probably also identifies a typo on page 13, where it says: "This estimated a sample size of 1,134 is required to detect an effect size of 0.2 points on the..." which probably should read "This estimated a sample size of 1,134 is required to detect an effect size of d=0.20 on the..." As in the first version of the manuscript no clear connection between scale points and effect sizes is made which would be necessary to make the shift from effect sizes to scale points in that paragraph.
[Given that two of these comments refer to things that were typos and discussed before, I am sorry if they refer to an earlier version of the manuscript, but it was the one I got from the BMJOpen submission system as the current proof] VERSION 3 -AUTHOR RESPONSE Reviewer 3 states: 1) On page 9 the authors added "Additionally, participants will be stratified by industry." Please specify this stratification exactly here and potentially in the analysis section if used as a design variable (which categories are being used and if used in analysis, how will they be incorporated)? RESPONSE: We thank the reviewer for raising this important oversight which was based on previous plan for analysis which has since been modified and this section has accordingly been removed." Nevertheless, in the version in the online system the sentence about stratification is still included.
We are not sure if the reviewer has seen the updated file, but it has now been removed.
2) Additionally, I am still not clear on what statistical model the authors will use and how it is connected to their hypotheses. It is stated that a repeated-measurement mixed model will be used to analyse the data for the primary outcome (and that the sample size calculation was performed for this model). Nevertheless, the hypothesis the authors set out to test is the difference in PHQ-9 sum scores at 3 months -which necessitates a planned comparison at only that assessment, which can be derived from the results of the mixed model (either via a post-hoc test or a contrast). If this is what the authors have in mind, this should be state din the statistical analysis section. It is clear from the history so far that there are differing opinions on what detail needs to be reported at this stage, but I repeat this point since it could have consequences for the sample size calculation: If the analysis was planned for a repeated measures mixed model without specification, the sample size would only be enough to inform a an overall test, i.e. whether across the pre-and post-measurements between the two groups in any form overall an effects size of d=.20 can be found. What the actual question is, is whether at 3-months a difference of d=.20 can be found. (this is another place whether this clarification could be made)
The planned comparison stated: "An a priori planned comparison of change from baseline across the 3-month follow up period will be used to test the primary hypothesis." This has been further clarified in the sample size section: "This estimated a sample size of 1,134 is required to detect an effect size of d=0.20 on the total PHQ-9 scale score at 3-month follow-up." We hope this sufficiently addresses the reviewer's concerns 3) This probably also identifies a typo on page 13, where it says: "This estimated a sample size of 1,134 is required to detect an effect size of 0.2 points on the..." which probably should read "This estimated a sample size of 1,134 is required to detect an effect size of d=0.20 on the..." As in the first version of the manuscript no clear connection between scale points and effect sizes is made which would be necessary to make the shift from effect sizes to scale points in that paragraph.
This has been corrected to read: "This estimated a sample size of 1,134 is required to detect an effect size of d=0.20 on the total PHQ-9 scale score at 3-month follow-up"
